This article contains content that is written like
an advertisement. (June 2023) |
Company type | Joint venture |
---|---|
Industry | Pharmaceutical industry |
Founded | 2009 |
Headquarters | London, England, UK |
Area served | Worldwide |
Key people | Deborah Waterhouse ( CEO) |
Products | Pharmaceuticals |
Owners | |
Number of employees | c. 1,100 (2023) |
Website |
viivhealthcare |
ViiV Healthcare ( /ˈviːv/ VEEV) is a British multinational pharmaceutical company specializing in the research and development of medicines to treat and prevent HIV/AIDS, with its global headquarters in London. The company was created as a joint venture by GSK and Pfizer in November 2009, with both companies transferring their HIV assets to the new company. [1] In 2012, Shionogi joined the company. As of December 2023, 76.5% of the company is owned by GSK, 13.5% by Pfizer and 10% by Shionogi. [2] According to The Financial Times, the company’s co-ownership structure may change depending on the achievement of certain milestones. [1]
ViiV Healthcare's products have a market share of approximately 32% of the global HIV therapy market, making it the second-largest healthcare company in the sector, after Gilead Sciences. [3]
ViiV Healthcare's global headquarters are in Brentford, Greater London in the United Kingdom, and the company has sites in a number of other countries including the United States, Australia, Belgium, Canada, France, Germany, Italy, Japan, Mexico, the Netherlands, Portugal, Puerto Rico, Russia, Spain and Switzerland. [4]
The company markets 17 products: [5]
ViiV Healthcare has stated that it will continue the not-for-profit pricing schemes that Pfizer and GlaxoSmithKline had been involved in prior to the setting up of the company. This program covers all low- and middle-income countries, as well as all of Sub-Saharan Africa. [7]
The company has also granted voluntary licenses to 14 generics companies to enable the low-cost manufacture and sale of generic versions of the company's products in specific countries and/or regions. [7] [8]
In March 2020, ViiV Healthcare announced the initiation of a study in partnership with University of South Carolina's Ryan White Program to determine the effectiveness of ride-sharing services in improving access to care for people living with HIV. [9]